Scintigraphic Assessment Following Klean-Prep® or Moviprep®

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00896246
Recruitment Status : Completed
First Posted : May 11, 2009
Last Update Posted : May 12, 2009
Information provided by:

May 8, 2009
May 11, 2009
May 12, 2009
September 2006
October 2006   (Final data collection date for primary outcome measure)
To assess the impact of Moviprep® and Klean-Prep® on time of colonic transit of the contents of the colon in comparison to baseline [ Time Frame: 2-4 days ]
Same as current
Complete list of historical versions of study NCT00896246 on Archive Site
  • To assess the gastrointestinal transit of Moviprep® and Klean-Prep® in comparison to baseline [ Time Frame: 2-4 days ]
  • To determine gastric emptying of Moviprep® and Klean-Prep® [ Time Frame: 2-4 days ]
  • To collect information about stool weight, visual characteristics and distribution of the radiolabel [ Time Frame: 2-4 days ]
Same as current
Not Provided
Not Provided
Scintigraphic Assessment Following Klean-Prep® or Moviprep®
Scintigraphic Assessment of Gastrointestinal Transit Following Administration of Klean-Prep® (4L) or Moviprep® (2L) to Healthy Volunteers.
This was a phase 1, open-label, randomized study, designed to assess the impact of Moviprep® or Klean-Prep® on gastrointestinal transit. It was performed in two parallel groups with Part A in two groups of four subjects preceding Part B, which was performed in two groups of 12 subjects. Subjects attended a pre-study medical within 28 days of dosing and a post-study medical 5-10 days after the final dose. Within both Part A and Part B, subjects were required to attend the clinical unit for 2 study periods. Part A consisted of a baseline period to determine individual reference times for gastrointestinal transit. Part B was the test period in which gastrointestinal transit following the administration of the test preparations was assessed.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Gastric Emptying
  • Healthy
  • Drug: Klean-Prep®
    Four litres of solution administered orally as a divided dose.
  • Drug: Moviprep®
    Two litres of solution administered orally as a divided dose
  • Active Comparator: Klean-Prep®
    1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
    Intervention: Drug: Klean-Prep®
  • Experimental: Moviprep®
    1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
    Intervention: Drug: Moviprep®
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
November 2006
October 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy males;
  2. Aged 18-65 years;
  3. Body Mass Index of 18-35 kg/m2;
  4. Must be willing and able to participate in the whole study and must provide written informed consent.

Exclusion Criteria:

  1. Participation in a clinical research study involving investigational drugs or dosage forms within the previous 3 months;
  2. Subjects who have previously been enrolled in this study;
  3. Subjects who have ever sought advice from or been referred to a GP or counsellor for abuse or misuse of alcohol, non medical drugs, medicinal drugs or other substance abuse e.g. solvents;
  4. Subjects who admit to any current or previous use of Class A drugs such as opiates, cocaine, ecstasy, LSD (d lysergic acid diethylamide) and intravenous amphetamines. Subjects who admit to occasional past use of cannabis will not be excluded as long as they have a negative drugs of abuse test and have abstained from cannabis use for at least 3 months;
  5. Positive drugs of abuse test result;
  6. Regular alcohol consumption > 21 units per week (1 Unit = ½ pint beer, a 25 mL shot of 40% spirit or a 125 mL glass of wine);
  7. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening;
  8. Radiation exposure from clinical trials, including that from the present study and from diagnostic x rays but excluding background radiation, exceeding 5 mSv in the last twelve months or 10 mSv in the last five years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study;
  9. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the PMI;
  10. History of gastrointestinal surgery (with the exception of appendectomy unless it was performed within the previous 12 months);
  11. History of clinically significant cardiovascular, renal, hepatic, respiratory and particularly gastrointestinal disease, especially peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease or Irritable Bowel Syndrome;
  12. Subjects with a hypersensitivity to any of the ingredients in either Moviprep® or Klean- Prep®;
  13. Diarrhoea or constipation in the 7 days before the predicted first study day. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day.
  14. Subjects will be excluded from the study if they are considered by the PMI to be at risk of transmitting, through blood or other body fluids, the agents responsible for AIDS (Acquired Immunodeficiency Syndrome), other sexually transmitted disease or hepatitis. This will be assessed by the use of a question which requires that a potential subject decides whether he fulfills any category included on a reference card. If the answer is 'yes', the subject is excluded from the study;
  15. Positive HBV, HCV or HIV results;
  16. Subjects receiving prohibited medication as described in Section 7.4. Subjects must not stop taking a prescribed medication for the purpose of entering the study;
  17. Subjects with a history of phenylketonuria or glucose-6-phosphate dehydrogenase deficiency;
  18. Failure to satisfy the PMI of fitness to participate for any other reason.
Sexes Eligible for Study: Male
18 Years to 65 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
NRL994-01/2007 (GLO)
Not Provided
Not Provided
Dr Hans-Jürgen Gruss, Norgine Ltd
Not Provided
Study Director: Hans-Jürgen Gruss, MD Norgine
Principal Investigator: Philip Evans, MB ChB MRCS Pharmaceutical Profiles Ltd
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP